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Human β-Defensin 2 in Primary Sclerosing Cholangitis
Cindy Chang, MS1, Ana Lleo, MD, PhD2,3, Anchasa Kananurak, PhD4, Fabio Grizzi, PhD5, Koichi Tsuneyama, MD, PhD6,
Pietro Invernizzi, MD, PhD7,8, Charles L. Bevins, MD, PhD4 and Christopher L. Bowlus, MD1
OBJECTIVES: Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease of the bile ducts frequently associated with
inflammatory bowel disease (IBD), suggesting an important role for the gut–liver axis. Defensins are small (3.5–4.5 kDa) anti-
microbial peptides that contribute to innate immunity at mucosal surfaces and have been implicated in IBD. The aim of this study
was to investigate copy number variation of the gene (DEFB4) encoding human β-defensin 2 (HBD2) and protein expression of
HBD2 in PSC.
METHODS: US and Italian PSC cases and unaffected controls (US PSC patients n= 89, US controls n= 87; Italian PSC patients
n= 46, Italian controls n= 84) were used to estimate HBD2 gene copy number by both quantitative real-time PCR and paralog ratio
test. Serum levels of HBD2 were measured by enzyme-linked immunosorbent assay and liver expression was analyzed by
immunohistochemistry.
RESULTS: Mean serum levels of HBD2 were significantly greater in PSC (1,086± 1,721 ng/μl) compared with primary biliary
cholangitis (544± 754 ng/μl), ulcerative colitis (417± 506 ng/μl), and healthy controls (514± 731 ng/μl) (P= 0.02). However, no
significant differences between the frequencies of high DEFB4 gene copy number, defined by44 copies, and PSC were found in
the US, Italian, or combined cohorts. Importantly, a high number of biliary ducts were found immunopositive in PSC samples
compared with controls.
CONCLUSIONS: Our data show that HBD2 serum levels and tissue expression are increased in PSC subjects, suggesting that this
arm of innate immunity may be important in the etiopathogenesis of PSC.
Clinical and Translational Gastroenterology (2017) 8, e80; doi:10.1038/ctg.2017.8; published online 16 March 2017
Subject Category: Pancreas and Biliary Tract
INTRODUCTION
Primary sclerosing cholangitis (PSC) is a rare chronic
cholestatic liver disease, affecting 6 per 100,000 people in
the United States, more commonly men. It often affects
subjects in the third to fourth decade of life and leads to diffuse
stricturing and thickening of intrahepatic and/or extrahepatic
ducts.1 Although the etiology of PSC is not fully known, it is
recognized to be an immune-mediated liver disease that has
autoimmune features including the presence of autoantibo-
dies such as antinuclear antibodies and perinuclear antineu-
trophil cytoplasmic.2 No effective treatment has been found to
slow or alter the progression of PSC, and it remains a leading
cause of liver transplantation.3 Median survival from time of
diagnosis to liver-related death or liver transplantation is
12–15 years.4 Interestingly, 75% of PSC patients are
coaffected with inflammatory bowel disease (IBD)5 and the
dysregulation of the key genetic, immunologic, and micro-
biome compounds of the gut–liver axis are suggested to be the
basis for both IBD and PSC.6
Defensins are small (3.5–4.5 kDa) anti-microbial peptides
that contribute to innate immunity at mucosal surfaces and
have been implicated in IBD. These peptides have bactericidal
effects by damaging bacterial cell membranes and/or inhibit-
ing cell wall biosynthesis. Additionally, some defensins
possess cytokine-like activities.7,8 For example, certain
defensins use CCR6 to attract dendritic cells.9 There are two
classes of defensins in humans: α and β, which are divided,
based on the position of three intermolecular disulfide
bridges.8,10 There are two groups of α-defensins: neutrophil
α-defensins (HNP-1, -2, and -3) and enteric α-defensins, which
are produced by the Paneth cells that reside in the small
intestinal crypts (HD-5 and -6).8,10,11 Human β-defensins
(HBDs) are produced by various epithelial cells such as the
skin, respiratory, and gastrointestinal tract8 and have been
found distributed on the epithelium of several organs including
the liver.12 There are three clusters of β-defensin genes: two
on chromosome 20 and one on chromosome 8p23.1.7
Included in a ~ 260 kb cluster on chromosome 8p23.1 are
genes encoding HBDs 2–7, with the gene encoding HBD2
(DEFB4) being the principal focus of this investigation. The
copy number of this entire gene cluster is polymorphic and
ranges from 2 to 12 copies per individual.7,13,14 In terms of
1Division of Gastroenterology and Hepatology, University of California Davis Medical Center, Sacramento, California, USA; 2Liver Unit and Center for Autoimmune Liver
Diseases, Humanitas Clinical and Research Center, Milan, Italy; 3Department of Biomedical Sciences, Humanitas University, Milan, Italy; 4Department of Microbiology and
Immunology, University of California Davis School of Medicine, Davis, California, USA; 5Department of Immunology and Inflammation, Humanitas Clinical and Research
Center, Milan, Italy; 6Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan; 7Division of Rheumatology, Allergy, and Clinical
Immunology, University of California at Davis School of Medicine, Davis, California, USA and 8International Center for Digestive Health, Department of Medicine and
Surgery, University of Milan-Bicocca, Milan, Italy
Correspondence: Christoper L. Bowlus, MD, Division of Gastroenterology and Hepatology, University of California Davis Medical Center, 4150 V Street, PSSB 3500,
Sacramento, California 95817, USA. E-mail: clbowlus@ucdavis.edu
Received 30 August 2016; accepted 5 January 2017
Citation: Clinical and Translational Gastroenterology (2017) 8, e80; doi:10.1038/ctg.2017.8
& 2017 the American College of Gastroenterology 2155-384X/17
www.nature.com/ctg
expression of specific HBDs, HBD1 is constitutively expressed
in epithelial cells, while expression of HBD2 and HBD3 are
inducible by inflammatory triggers.13 Variations in β-defensin
expression and genomic copy numbers have been linked to
several autoimmune and inflammatory diseases15 including
celiac disease,16 ulcerative colitis,17 Crohn’s disease,13,18 and
psoriasis.14 Based on the high rate of coincidence between
PSC and IBD and the key role of the gut–liver axis in PSC
pathogenesis, we undertook this study to investigate whether
HBD gene copy number variation and/or expression are
associated with PSC.
METHODS
Subjects. Fresh heparinized peripheral blood samples were
obtained from two cohorts of PSC patients and controls
located either in the United States or Italy (US PSC patients
n= 92, US controls n=87; Italian PSC patients n=93, Italian
controls n= 150). All patients had large duct PSC and had not
had a liver transplant at the time of enrollment. Serum was
collected from a subset of PSC patients in the US cohort
(n=43). Additional serum was collected from healthy (n= 37)
and disease controls including primary biliary cholangitis
(PBC) (n= 37) and ulcerative colitis (UC) (n= 42). Liver
biopsies were performed for diagnostic purposes; healthy
tissue was obtained from liver metastasis resection. Table 1
illustrates the clinical characteristics of the PSC patients
enrolled. All cases met accepted criteria for the diagnosis of
PSC,3 PBC,19 or UC.20 Serum liver function tests were
performed using routine laboratory methods. Subjects were
excluded from the study if they had malignancies or were
using immunosuppressive drugs. Patients and controls were
matched for age and sex. The study was approved by the
Institutional Review Board of the University of California at
Davis (Davis, CA), and all subjects provided written, informed
consent before enrollment.
HBD gene copy number. DNA was extracted from periph-
eral blood mononuclear cells using standard commercial kits.
Gene copy number (GCN) was estimated by two methods
including quantitative RT-PCR (qPCR) and paralog ratio test
(PRT) as described previously.18,21,22 In principle, both
methods rely upon comparing the amplification of target
sequences within the cluster of β-defensin genes and single
copy genes outside of the cluster. The qPCR method for the
measuring GCN has been criticized due to its propensity to
produce ambiguous results. Specifically, the results of a test
for GCN should result in an integer. However, with qPCR it is
common to have fractions of the GCN and it is not clear how
best to handle these situations. PRTovercomes this situation
and in comparative studies has been shown to more accurate
compared with qPCR.21,22 To assess the HBD gene copy
number in our US and Italian cohorts, we used a triplex
PRT method previously published in Aldohous et al.21 and
Armour et al.22 described in detail in the Supplementary
Materials online.
As our “gold standard” control DNA we used six samples
from the Human Random Control DNA Panels from European
Collection of Cell Cultures purchased from Sigma (catalog
number HRC-1 (2 μg)). Similar to our samples, standard
control DNA was also diluted to 10 ng/μl. The six samples
used from the panel were C0207, C0088, C0849, C0940,
C0969, and C0913. The expected copy numbers for
β-defensin of the standard control DNA are 5, 4, 6, 4, 5,
and 3, respectively.
Serum ELISA of HBD2. To determine levels of HBD2
protein in serum, we used the HBD2 ELISA (enzyme-linked
immunosorbent assay) Kit from Peprotech (Rocky Hill, NJ,
catalog number 900-K172). We coated ELISA microplates
with antigen-affinity-purified goat anti-HBD2+ D-mannitol
capture antibody at a concentration of 100 μg/ml overnight.
We then performed ELISA on the serum samples diluted 1:2
to 1:10 according to the manufacturer’s protocol using
biotinylated antigen-affinity-purified goat anti-HBD2+ D-man-
nitol detection antibody at 100 μg/ml concentration and
avidin-HRP conjugate and ABTS liquid substrate. Data for
the ELISA plate was obtained on an ELISA plate reader set at
405 nm with the wavelength correction set at 650 nm
(Molecular Devices, Sunnyvale, CA). Plates were monitored
every 5 min and data were read when the highest standard
concentration was at 1.2 U.
Immunohistochemistry. For the immunohistochemistry
2–3-μm-thick sections of each surgical specimen were cut
and processed. After deparaffining and rehydration, the
sections were immersed in an antigen heat retrieval solution
(Diva Decloaker; Biocare Medical, Milan, Italy) and treated by
an antigen retrieval procedure by a Decloaking Chamber
(Biocare Medical), incubated with 3% H2O2 for 15 min to
quench endogenous peroxidase activity, treated with goat
anti-HBD2 polyclonal antibody (AbD Serotec, Hercules, CA;
AHP849) diluted 1:50 and incubated overnight at 4 °C), and
then incubated with the goat HRP-Polymer Detection Kit
(Biocare Medical). 3,3′-Diaminobenzidine tetrahydrochloride
(Biocare) was used as a chromogen to yield brown reaction
Table 1 Characteristics of the patients with primary sclerosing cholangitis from the two cohorts included in the study
Features US PSC (n= 92) Italian PSC (n= 93)
General
Male sex, n (%) 54 (59) 53 (57)
Age (years), median (range) 47 (15–76) 48 (18–76)
Duration of disease (years), median (range) 5 (0–25) 10 (3–35)
Colitis, n (%) 69 (75) 67 (72)
PSC, primary sclerosing cholangitis; US, United States.
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products. The nuclei were lightly counterstained with hema-
toxylin solution. Immunoreactivity was semiquantitatively
scored as follows: 0, absence of immunoreactivity; 1, weak;
2, moderate; and 3, intense expression. All images were
digitized at x40 objective magnification.
Statistical analysis. Power analysis for the association
study was performed using the data of frequency and effect
in the Hollox psoriasis GCN analysis.14 Assuming an effect
size of 0.37 with an α of 0.05, we would have 40.95 power
with a total sample size of 150. Comparison of GCNs was
performed using χ2 analysis. A dichotomous variable of “low”
and “high” GCN was defined by o4 copies and ≥4 copies.
This cutoff was chosen based on the median GCN of 4 and
use of this cutoff in prior studies. Continuous variables were
compared using the Kruskal–Wallis test.
RESULTS
Association of HBD2 (DEFB4) GCN and PSC. We
compared the reproducibility of the qPCR assay and the
concordance of results tested by qPCR and PRTon the same
samples. Three hundred six samples were tested two times
by qPCR (US PSC patients n=89, US controls n= 87; Italian
PSC patients n=46, Italian controls n= 84). The mean GCN
difference between samples was 0.7±1.8 (mean± s.d.). The
interassay correlation between GCNs estimated by qPCR
was relatively poor (Figure 1a, r= 0.526, Po0.01), with the
greatest variability occurring at the extreme low and high
ranges of the assays (Figure 1b). Two hundred and seventy-
four samples were tested by qPCR and PRT (US PSC
patients n=79, US controls n=85; Italian PSC patients
n=33, Italian controls n=77). The mean difference between
the GCNs estimated by these methods was 0.7±1.1
Figure 1 Comparison of assays estimating DEFB4 gene copy number. (a) Comparison of gene copy number (GCN) estimates of identical samples tested in two separate
quantitative RT-PCR (qPCR) experiments and (b)the differences between qPCR assays according to the rounded GCN of the second assay. (c) Comparison of the rounded GCN
in the second qPCR assay vs. GCN estimated in the same samples using the paralog ratio test (PRT) assays. (d) Histogram of the differences in GCN estimated by qPCR and
PRT on identical samples.
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(mean± s.d.). Correlation of the estimated GCN by qPCR
rounded to the nearest integer and by PRT was good
(r= 0.772, Po0.001; Figure 1c). Because PRT has been
demonstrated to be superior to qPCR,21,22 further analysis of
disease associations were conducted only with the PRT
method results.
Comparisons of the mean and median GCNs in the four
cohorts are shown in Table 2. No significant differences
between the frequencies of high DEFB4 GCN, defined by44
copies, and PSC were found in the US, Italian, or combined
cohorts (Table 3).
Moreover, we sought to determine if there was any
association between DEFB4 GCN and the presence of IBD
by comparing PSC cases with IBD to controls and PSC cases
without IBD (Table 4). No significant associations were found,
but this analysiswas limited to a subset of the US cohort due to
missing phenotypic data.
Serum levels of HBD2 in PSC are greater than in UC,
PBC, or healthy controls and correlate with DEFB4
GCN. We compared the serum levels of HBD2 from subjects
with PSC (n= 43), PBC (n=37), or UC (n=42), and healthy
controls (n=37). Mean serum levels of HBD2 were sig-
nificantly greater in PSC (1,086±1,721 ng/μl) compared with
PBC (544±754 ng/μl), UC (417±506 ng/μl), and healthy
controls (514±731 ng/μl) (P=0.02) (Figure 2a). Within the
PSC cohort, 23 subjects had both serum HBD2 levels and
GCN measured. There was a significant correlation between
the GCN and serum HBD2 levels (Spearman's rank test,
r=0.377, P= 0.038) (Figure 2b).
HBD2 liver expression. A high number of biliary ducts were
immunopositive in PSC samples, while biliary cells from
controls appeared to not express the protein (Figure 3).
Importantly, in PSC liver HBD2 protein was not observed in
hepatocytes, but was noted in resident macrophages (Kupffer
cells), vascular structures (of different size), and, in some
cases, cells associated with fibrous tissue and inflammatory
infiltrates. The images show prototypical examples of HBD2
expression in PSC liver within Kupffer cells (a), bile ducts and
vessels (arteries and veins) (b), and in the fibroinflammatory
component (c).
DISCUSSION
HBDs are anti-microbial peptides important in innate immunity
that have been implicated in many inflammatory diseases,
including IBD.7,8,15 Previous studies have demonstrated that,
while HBD1 appears to be present in biliary epithelium
under physiological conditions, HBD2 is not physiologically
expressed but may be induced in large intrahepatic bile ducts,
in response to local infection and active inflammation.5,12 The
high rate of coincidence between PSC and IBD and the key
role of the gut–liver axis in PSC pathogenesis, led us to
investigate whether HBD2 gene (DEFB4) copy number
variation and expression were associated with PSC.
We herein show that HBD2 is expressed in biliary epithelial
cells from PSC patients and that serum levels are increased
compared with controls. Using the most accurate means of
estimating GCN in two large cohorts of PSC patients, we did
not find any significant differences in DEFB4 GCN in PSC
compared with healthy controls. However, serum levels of
HBD2 in PSC correlated with the GCN.
Hypotheses surrounding the connection between PSC and
IBD generally suggest that molecules from the gastrointestinal
tract, which is rich with microbes, translocate to the liver
causing inflammation of the bile ducts. One hypothesis is that
bile duct epithelial cells are activated by a bacterial pathogen
that travels from the gut to the liver leading to chronic
inflammation.4,23 An alternate hypothesis suggests that
lymphocytes that are activated in the bowel of IBD patients
Table 2 Comparison of human β-defensin 2 gene copy number in PSC cases
and controls
Cohort Mean S.d. Median Range
US
PSC 4.43 1.04 4 2–7
Controls 4.35 1.00 4 2–8
Italy
PSC 4.51 0.93 4 2–7
Controls 4.30 0.99 4 2–8
PSC, primary sclerosing cholangitis; US, United States.
Table 3 Frequency of low (o4) and high (44)HBD2 gene copies in PSC cases
and healthy controls from the US and Italy
Cohort HBD2 GCN Total χ2 P value
≤4 44
US
PSC 49 34 83
Control 53 32 85
Total 102 66 168 0.194 P= 0.660
Italy
PSC 42 38 80
Control 87 57 144
Total 129 95 224 1.320 P= 0.251
Total
PSC 91 72 163
Control 140 89 229
Total 231 161 392 1.108 P= 0.292
GCN, gene copy number; HBD2, human β-defensin 2; PSC, primary sclerosing
cholangitis; US, United States.
Table 4 Frequency of low (≤4) and high (44) HBD2 gene copies in PSC cases
with and without IBD and healthy controls from the US
Cohort HBD2
GCN
Total χ2 P value
≤4 44
US
PSC with IBD 28 20 48
Control 53 32 85 0.208 P= 0.648
PSC without IBD 7 8 15 0.117 P= 0.733
GCN, gene copy number; HBD2, human β-defensin 2; IBD, inflammatory bowel
disease; PSC, primary sclerosing cholangitis; US, United States.
HBD2 Expression in PSC
Chang et al.
4
Clinical and Translational Gastroenterology
are aberrantly recruited to extraintestinal sites (i.e., liver) via
expression of adhesion molecules and chemokines normally
restricted to the gut at sites such as bile duct epithelium.4,23
Thus, an impaired anti-microbial defense through altered HBD
expression at the liver might provide inadequate barrier
function leading to a failure to clear pathogens and resulting
in a chronic inflammatory response. Moreover, expression of
HBD2 is highly inducible in response to many proinflammatory
mediators in a range of cell types.13
It has been suggested that HBD2 may contribute to host
defense not only through microbial activity but also by
recruiting immune cells to sites of inflammation and
infection.24 HBD2 attracts T cells, especially Th17 and Th22
cells, and immature dendritic cells through CCR6.9 CCR6 has
been implicated in host defense and inflammation at epithelial
surfaces and Th17 and Th22 likewise have high inflammatory
potential, especially in the skin and gut.25 HBD2 and CCL20
have similar tertiary structures as well as several positively
charged residues so that even though they lack sequence
similarity both ligands compete for binding to the CCR6
receptor.25 Additionally, HBD2 has been shown to be a potent
chemoattractant for neutrophils.24,25 This suggests an alter-
nate mechanism through which HBD2 may act in a disease
state aside from decreased barrier function.
We anticipated that our control samples would have a
median of four copies of the gene encoding HBD2
Figure 2 Serum levels of human beta-defensin 2. (Left) Mean serum human β-defensin 2 (HBD2) levels± 1 s.e. in healthy controls (n= 37), primary sclerosing cholangitis
(PSC) (n = 43), primary biliary cholangitis (PBC) (n= 37), and ulcerative colitis (UC) (n= 42). (Right) Serum levels of HBD2 correlate with HBD2 gene copy number in PSC
patients (r= 0.377, P= 0.038).
Figure 3 Immunohistochemistry analysis of human β-defensin 2 (HBD2) expression. (a) The images show prototypical examples of HBD2 expression in Kupffer cells (1), bile
ducts and vessels (arteries and veins) (2), and in the fibroinflammatory component (3). Normal liver tissue is showed in (4). All the images have been digitized at x40 objective
magnification. (b) (1) HBD2 expression in bile ducts is greater in primary sclerosing cholangitis (PSC) patients with inflammatory bowel disease (IBD) compared to normal
controls (CTR); (2) HBD2 expression in different cell types in liver tissue of PSC patients are presented. Immunoreactivity was semiquantitatively scored as follows: 0, absence of
immunoreactivity; 1, weak; 2, moderate; and 3, intense expression. All the images were digitized at objective magnification x40.
HBD2 Expression in PSC
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(DEFB4).13,14,18We observed this samemedian value by both
qPCR and PRT approaches. In contrast, conflicting results
have been reported in studies on HBD GCN variation in
Crohn’s disease.13,18 Fellermann et al.,18 using a qPCR
method, showed an association of lower DEFB4 copy number
with an increased risk of developing colonic Crohn’s disease.
They concluded that there was an impaired anti-microbial
defense in individuals witho4 copies and this weakened anti-
bacterial barrier in the colon led to chronic inflammation and
Crohn’s disease. On the other hand, Bentley et al.13 also using
a qPCR method, showed an association of greater than 4
DEFB4GCN with a higher risk of developing Crohn’s disease.
This discrepancy was thoughtfully discussed26 and remains
unresolved. Additionally, Bentley et al.13 suggests that the
association of HBD2GCN and HBD2 protein production is not
a straightforward gene dosage effect, possibly attributable to
DEFB4 being highly inducible by inflammatory stimuli. In
psoriasis, a higher genomic copy number for HBD2 genes is
significantly associated with disease risk14 and HBD2 serum
levels are associated with clinical severity.27 Beta-defensin-2
protein is a serum biomarker for disease activity in psoriasis
and reaches biologically relevant concentrations in lesional
skin. Based on these findings and those of our current study,
serum HBD2 is an attractive candidate as a potential
biomarker of disease activity in PSC.
In this study, we used a similar PRT method that is more
accurate because it eliminates the possibility of errors due to
differential amplification efficiency. Using both qPCR and PRT
approaches to estimate DEFB4 GCN, we observed no
association of GCN with PSC disease. The lack of an
association in this study does not exclude the possibility that
an effect too small to be detected by the current study might
exist. However, our study was designed to have a total sample
size of 150, which would give 0.95 power to identify a genetic
association between a GCN 44 and disease with an odds
ratio of 1.73. Based on the distribution of GCN from our study,
612 samples would be necessary to have 0.80 power to
identify a similar association with an estimated odds ratio of
1.34. Recent development of large cohorts of PSC cases used
in genome-wide association studies make such a study
feasible.
As suggested before, serum HBD2 protein levels may be
the determinative factor of disease activity and not HBD
genomic copy number. Our findings suggest that the PSC
disease state may not act through a straightforward gene
dosage effect. Recent studies have suggested that epige-
netics have a critical role in regulating inflammatory
responses.28 DNA methylation, histone acetylation, and other
epigenetic modifications lead to changes in gene expression.
A recent study by Yin and Chung28 in periodontitis, a chronic
oral inflammatory disease, showed differential epigenetic
regulation of DEFB4 in response to different oral bacteria.
Bacteria-induced expression of DEFB4 was regulated
through epigenetic mechanisms in gingival epithelial cells. A
decreased expression of DNA methyltransferase 1 and
histone deacetylase expression was found in response to
both an oral pathogen and non-pathogen.28 This may be a
possible mechanism that explains our finding of a higher
expression levels of HBD2 associated with PSC despite
finding no association of GCN with PSC. However, further
studies are necessary to establish a significant link between
HBD2 and PSC.
In conclusion, our study suggests that HBD2 may have a
role in the development of or response to PSC. Future studies
should investigate the mechanisms of this association and the
potential effects of HBD2 on PSC acting through its anti-
microbial activity or chemotactic function.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Primary sclerosing cholangitis (PSC) is a rare disease of the
bile ducts frequently associated with inflammatory bowel
disease (IBD).
✓ Human β-defensin 2 (HBD2) is an anti-microbial peptide
that has been linked to IBD and other autoimmune
conditions.
✓ Gene copy number (GCN) variants in the DEFB4 gene that
encodes HBD2 and other factors may influence the
expression of the HBD2 protein.
WHAT IS NEW HERE
✓ No differences in DEFB4 GCN were found between PSC
and normal controls.
✓ Serum and tissue levels of HBD2 were greater in PSC
compared with IBD and other disease controls.
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